Key View
- Lung cancer prevalence in Mainland China will continue to drive high levels of the disease both regionally and globally.
- Investment in lung cancer clinical trials globally, as well as in Asia, is influenced by the rate of disease and the percentage of GDP spent on R&D.
- China-based trial sponsors’ preference for China-only trials will limit global competitiveness and market access outside China.
Lung cancer prevalence in Mainland China will continue to drive high levels of the disease both regionally and globally. Lung cancer cases across the continent of Asia represented two thirds of global cases in 2022 (latest available data), at 1.5mn cases. While this number is partially accounted for by population, the age standardised rate of lung cancer incidence in Asia was comparable with Europe. Markets in Asia occupied nine of the top 20 markets with the most lung cancer cases. The majority of Asian markets impacted by high levels of lung cancer are emerging markets (EMs) with less well-developed healthcare systems to support screening programmes. Lung cancer cases in China are the primary driver of high rates in Asia, with cases in the market accounting for 68% of all cases in Asia. China has limited tobacco control policies, only banning smoking in two of the eight public spaces tracked by the WHO. This is below the Asia-Pacific average of six places. We therefore expect that lung cancer cases in China will continue to drive up both regional and global levels, alongside other factors such as an ageing population in Asia more broadly.
Mainland China To Sustain Global Lung Cancer Burden, Driving Domestic Investment And R&D In Therapeutics
Mainland China faces a significant challenge with lung cancer, one of the leading causes of mortality in the region. The country’s vast population and high smoking rates contribute to this burden. As a result, the government recognizes the urgent need to address the issue, fueling substantial investment in healthcare and research.
This rising health concern is catalyzing domestic investment in the development of advanced therapeutics. China’s biotech industry is increasingly focusing on innovative treatments, including targeted therapies and immunotherapies, to improve patient outcomes. Local pharmaceutical companies are collaborating with international firms to harness global expertise, accelerating drug development and approval processes.
Furthermore, China is prioritizing research and development (R&D) to foster homegrown solutions. The government’s support for R&D infrastructure and talent cultivation is poised to make significant strides in combating lung cancer. As China continues to enhance its healthcare capabilities, it could play a pivotal role in reducing the global burden of lung cancer.
